David A. Ahlquist

David A. Ahlquist

Auto-generated profile, based on publicly available information

David A. Ahlquist

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2000 in Gastroenterology
Verified
Journal Article
Open access
PDF file
DADavid A. Ahlquist
David A. Ahlquist
JSJoel E. Skoletsky
Joel E. Skoletsky
KBKevin A. Boynton
Kevin A. Boynton
JHJonathan J. Harrington
Jonathan J. Harrington
DMDouglas W. Mahoney
Douglas W. Mahoney
ASAnthony P. Shuber
Anthony P. Shuber
Background & Aims: Assay of altered DNA exfoliated into stool represents an intriguing approach to screen for colorectal neoplasia, but multiple markers must be targeted because of genetic heterogeneity. We explored the feasibility of a stool assay panel of selected DNA alterations in discriminating subjects with colorectal neoplasia from those without. Methods: Freezer-archived stools were analyzed in blinded fashion from 22 patients with colorectal cancer, 11 with adenomas ≥1 cm, and 28 with endoscopically normal colons. After isolation of human DNA from stool by sequence-specific hybrid capture, assay targets included point mutations at any of 15 sites on K-ras, p53, and APC genes; Bat-26, a microsatellite instability marker; and highly amplifiable DNA. Results: Analyzable human DNA was recovered from all stools. Sensitivity was 91% (95% confidence interval, 71%–99%) for cancer and 82% (48%–98%) for adenomas ≥1 cm with a specificity of 93% (76%–99%). Excluding K-ras from the panel, sensitivities for cancer were unchanged but decreased slightly for adenomas to 73% (39%–94%), while specificity increased to 100% (88%–100%). Conclusions: Assay of altered DNA holds promise as a stool screening approach for colorectal neoplasia. Larger clinical investigations are indicated.

1 February 2012 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
DADavid A. Ahlquist
David A. Ahlquist
HZHongzhi Zou
Hongzhi Zou
MDMichael Domanico
Michael Domanico
DMDouglas W. Mahoney
Douglas W. Mahoney
TYTracy C. Yab
Tracy C. Yab
GLGraham P. Lidgard
Graham P. Lidgard

7 October 2008 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
DADavid A. Ahlquist
David A. Ahlquist
DSDaniel J. Sargent
Daniel J. Sargent
CLCharles L. Loprinzi
Charles L. Loprinzi
TLTheodore R. Levin
Theodore R. Levin
DRDouglas K. Rex
Douglas K. Rex
SHShauna L. Hillman
Shauna L. Hillman
Stool DNA testing is a new approach to colorectal cancer detection. Few data are available from the screening setting. To compare stool DNA and fecal blood testing for detection of screen-relevant neoplasia (curable-stage cancer, high-grade dysplasia, or adenomas >1 cm). Blinded, multicenter, cross-sectional study. Communities surrounding 22 participating academic and regional health care systems in the United States. 4482 average-risk adults. Fecal blood and DNA markers. Participants collected 3 stools, smeared fecal blood test cards and used same-day shipment to a central facility. Fecal blood cards (Hemoccult and HemoccultSensa, Beckman Coulter, Fullerton, California) were tested on 3 stools and DNA assays on 1 stool per patient. Stool DNA test 1 (SDT-1) was a precommercial 23-marker assay, and a novel test (SDT-2) targeted 3 broadly informative markers. The criterion standard was colonoscopy. Sensitivity for screen-relevant neoplasms was 20% by SDT-1, 11% by Hemoccult (P = 0.020), 21% by HemoccultSensa (P = 0.80); sensitivity for cancer plus high-grade dysplasia did not differ among tests. Specificity was 96% by SDT-1, compared with 98% by Hemoccult (P < 0.001) and 97% by HemoccultSensa (P = 0.20). Stool DNA test 2 detected 46% of screen-relevant neoplasms, compared with 16% by Hemoccult (P < 0.001) and 24% by HemoccultSensa (P < 0.001). Stool DNA test 2 detected 46% of adenomas 1 cm or larger, compared with 10% by Hemoccult (P < 0.001) and 17% by HemoccultSensa (P < 0.001). Among colonoscopically normal patients, the positivity rate was 16% with SDT-2, compared with 4% with Hemoccult (P = 0.010) and 5% with HemoccultSensa (P = 0.030). Stool DNA test 2 was not performed on all subsets of patients without screen-relevant neoplasms. Stools were collected without preservative, which reduced detection of some DNA markers. Stool DNA test 1 provides no improvement over HemoccultSensa for detection of screen-relevant neoplasms. Stool DNA test 2 detects significantly more neoplasms than does Hemoccult or HemoccultSensa, but with more positive results in colonoscopically normal patients. Higher sensitivity of SDT-2 was particularly apparent for adenomas.

1 January 2017 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
VHVanessa L Hale
Vanessa L Hale
JCJun Chen
Jun Chen
SJStephen Johnson
Stephen Johnson
SHSean C. Harrington
Sean C. Harrington
TYTracy C. Yab
Tracy C. Yab
NCNicholas Chia
Nicholas Chia
Background: Adenomatous polyps are the most common precursor to colorectal cancer, the second leading cause of cancer-related death in the United States. We sought to learn more about early events of carcinogenesis by investigating shifts in the gut microbiota of patients with adenomas. Methods: We analyzed 16S rRNA gene sequences from the fecal microbiota of patients with adenomas (n = 233) and without (n = 547). Results: Multiple taxa were significantly more abundant in patients with adenomas, including Bilophila, Desulfovibrio, proinflammatory bacteria in the genus Mogibacterium, and multiple Bacteroidetes species. Patients without adenomas had greater abundances of Veillonella, Firmicutes (Order Clostridia), and Actinobacteria (family Bifidobacteriales). Our findings were consistent with previously reported shifts in the gut microbiota of colorectal cancer patients. Importantly, the altered adenoma profile is predicted to increase primary and secondary bile acid production, as well as starch, sucrose, lipid, and phenylpropanoid metabolism. Conclusions: These data hint that increased sugar, protein, and lipid metabolism along with increased bile acid production could promote a colonic environment that supports the growth of bile-tolerant microbes such as Bilophilia and Desulfovibrio. In turn, these microbes may produce genotoxic or inflammatory metabolites such as H2S and secondary bile acids, which could play a role in catalyzing adenoma development and eventually colorectal cancer. Impact: This study suggests a plausible biological mechanism to explain the links between shifts in the microbiota and colorectal cancer. This represents a first step toward resolving the complex interactions that shape the adenoma–carcinoma sequence of colorectal cancer and may facilitate personalized therapeutics focused on the microbiota. Cancer Epidemiol Biomarkers Prev; 26(1); 85–94. ©2016 AACR.

1 January 2005 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
NONeal K. Osborn
Neal K. Osborn
DADavid A. Ahlquist
David A. Ahlquist

1 March 2012 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
DADavid A. Ahlquist
David A. Ahlquist
WTWilliam R. Taylor
William R. Taylor
DMDouglas W. Mahoney
Douglas W. Mahoney
HZHongzhi Zou
Hongzhi Zou
MDMichael Domanico
Michael Domanico
GLGraham P. Lidgard
Graham P. Lidgard